Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06712524
Recruiting Not applicable

Effect of Different Surgical Approaches of Granulomatous Mastitis

NCT06712524 · tracked via the Priya Life Science China tracker
Sponsor
Hubei Cancer Hospital
Phase
Not applicable
Started
2024-11-01
Last updated
2024-12-02

Condition(s) studied

Breast-conserving Plastic SurgeryGranulomatous Mastitis

Investigational drug(s) / intervention(s)

Breast-conserving plastic surgeryTraditional breast surgery

Breast-conserving plastic surgery: The commonly used breast conserving plastic surgery includes tennis racket, bat wing, V/J breast plasty, Grisotti and so on.

Traditional breast surgery: Traditional breast surgery

Study summary

The objective of this study was to prospectively investigate the effects of different surgical approaches on the recurrence rate and aesthetic outcome of patients with granulomatous mastitis. The patients were divided into traditional surgery group and plastic surgery group.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Only the subjects who meet all the following criteria may be included in this study: 1. Ability to understand the study procedures and contents, and willingness to voluntarily sign the written informed consent form; 2. 18≤Age≤75 years old, female; 3. Histologically confirmed granulomatous mastitis; 4. low and moderate risk for anesthesia. Exclusion Criteria: The subjects who meet any of the following criteria shall not be included in this study: 1. Absolute and relative contraindication for surgery; 2. Previous history of breast cancer or other malignancies; 3. Pregnancy; 4. Any serious complications which caused patients not suitable to participate this study.

Primary outcome measure(s)

  • Recurrence rate — 2, 3, 5 year
    The recurrence rate of mastitis patients was compared between traditional surgery group and plastic surgery group.

Trial sites (1)

FacilityCityRegionStatus
Hubei Cancer Hospital Wuhan Hubei Recruiting

More Hubei Cancer Hospital trials in China

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade Recruiting
DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes Recruiting
SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer Recruiting
A Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignant Differentiation. Recruiting
CNCMT：a Multi-center, Prospective, Single-arm Study Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06712524 on ClinicalTrials.gov ↗ ← All trials in China